Tellgen Corporation

Shenzhen Stock Exchange 300642.SZ

Tellgen Corporation EBITDA for the year ending December 31, 2023: USD 23.76 M

Tellgen Corporation EBITDA is USD 23.76 M for the year ending December 31, 2023, a -22.72% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Tellgen Corporation EBITDA for the year ending December 31, 2022 was USD 30.75 M, a -22.38% change year over year.
  • Tellgen Corporation EBITDA for the year ending December 31, 2021 was USD 39.61 M, a 35.20% change year over year.
  • Tellgen Corporation EBITDA for the year ending December 31, 2020 was USD 29.30 M, a -10.40% change year over year.
  • Tellgen Corporation EBITDA for the year ending December 31, 2019 was USD 32.70 M, a 12.20% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
SV Wall Street
Shenzhen Stock Exchange: 300642.SZ

Tellgen Corporation

CEO Mr. Jian Er Yao
IPO Date April 21, 2017
Location China
Headquarters Building 1
Employees 574
Sector Healthcare
Industries
Biotechnology 3D Printing Cleaning Supplies Cosmetics Glass Personal Care Pharmaceuticals Vaccines
Description

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. It offers tumor markers, human papilloma virus test kits, ToRCH products, Y chromosome microdeletions test kits, and multiplex immunoassay systems. The company was founded in 2003 and is based in Shanghai, China.

StockViz Staff

February 3, 2025

Any question? Send us an email